Dr. Mark A. Schroeder, MD
Medical Oncology (Medical Oncology Physician)
4500 Forest Park Ave, Div Im Bone Marrow Transplant, 5th, 6th, 8th Fl
Saint Louis, MO 63108
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 372
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Cincinnati College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2006002068
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Memorial Hospital Belleville, IL
- Christian Hospital Northeast Saint Louis, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
- Alton Memorial Hospital Alton, IL
Medical groups
- Washington University (3,029 clinicians)
- Select Physical Therapy Holdings Inc (2,024 clinicians)
- Washington University Physicians in Illinois Inc (175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 372
- Services billed
- 35,079
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 15,480 | 36 |
| Injection, fosaprepitant, 1 mg | 3,750 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,250 | 54 |
| Injection, bortezomib, 0.1 mg | 980 | 14 |
| Injection, palonosetron hcl, 25 mcg | 520 | 32 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 464 | 87 |
| Insertion of needle into vein for collection of blood sample | 435 | 129 |
| Established patient office or other outpatient visit, 30-39 minutes | 230 | 104 |
| Injection, granisetron hydrochloride, 100 mcg | 220 | 13 |
| Injection of additional new drug or substance into vein | 201 | 66 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 248 |
| Lenalidomide | 174 |
| Pomalyst (pomalidomide) | 116 |
| Acyclovir Other prescribers in Saint Louis, MO | 92 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Saint Louis, MO | 91 |
| Eliquis (apixaban) Other prescribers in Saint Louis, MO | 66 |
| Oxycodone Hcl Other prescribers in Saint Louis, MO | 39 |
| Gabapentin Other prescribers in Saint Louis, MO | 37 |
| Dexamethasone Other prescribers in Saint Louis, MO | 29 |
| Cholestyramine (cholestyramine (with sugar)) Other prescribers in Saint Louis, MO | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $63,113 in total to this clinician.
| GlaxoSmithKline, LLC. | $63,113 |
|---|
| Consulting Fee | $63,113 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Feb 17, 2025 | Consulting Fee | $22,688 |
| GlaxoSmithKline, LLC. Aug 28, 2025 | Consulting Fee | $22,138 |
| GlaxoSmithKline, LLC. May 12, 2025 | Consulting Fee | $11,275 |
| GlaxoSmithKline, LLC. Nov 13, 2025 | Consulting Fee | $7,013 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $193,221 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexam…
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexam…
Janssen Research & Development, LLC - A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC - Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment
Roche Products Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.